ELOX Eloxx Pharmaceuticals Inc.

4.26
-0.25  -6%
Previous Close 4.51
Open 4.55
Price To Book 3.77
Market Cap 170,411,306
Shares 40,002,654
Volume 274,321
Short Ratio
Av. Daily Volume 279,036
Stock charts supplied by TradingView

NewsSee all news

  1. Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase™

    Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020 Positive Phase 2 topline data reported for ELX-02 in

  2. Eloxx Pharmaceuticals to Present at the Biotech Showcase™ 2020 on January 14, 2020

    WALTHAM, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  3. Eloxx Pharmaceuticals to Present at the Evercore ISI 2nd Annual HealthCONx on December 4th, 2019

    WALTHAM, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  4. Eloxx Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019

    WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  5. Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019

    WALTHAM, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ:ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due 1H 2020.
ELX-02
Cystic fibrosis
Phase 2 data released January 14, 2020.
ELX-02
Cystinosis

Latest News

  1. Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase™

    Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020 Positive Phase 2 topline data reported for ELX-02 in

  2. Eloxx Pharmaceuticals to Present at the Biotech Showcase™ 2020 on January 14, 2020

    WALTHAM, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  3. Eloxx Pharmaceuticals to Present at the Evercore ISI 2nd Annual HealthCONx on December 4th, 2019

    WALTHAM, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  4. Eloxx Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019

    WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  5. Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019

    WALTHAM, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ:ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  6. Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update

    -Presented Positive Phase 1 Data from SAD and MAD Studies at North American Cystic Fibrosis Conference -On track to report top line Phase 2 data in nephropathic cystinosis this quarter, preliminary results show cystine

  7. Eloxx Pharmaceuticals Presents Positive Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC)

    Eloxx presented findings from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies and additional preclinical data for ELX-02 Eloxx will provide an update on the Phase 2 programs for ELX-02

  8. Eloxx Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on November 5, 2019

    WALTHAM, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  9. Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial

    CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis Eloxx plans to conduct the U.S. portion of the Phase 2 clinical trial at Cystic Fibrosis Therapeutics

  10. Eloxx Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 3rd, 2019

    WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic

  11. Eloxx Pharmaceuticals to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases on September 24, 2019

    WALTHAM, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic